Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
A phase 3 trial of Avelumab, Talazoparib, Pemetrexed in ovarian cancer, run by Pfizer, active and no longer recruiting.
Overview
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing is a phase 3 interventional study registered as NCT05059522 by Pfizer, with 77 participants enrolled, started 2021-09-29 and due to reach its primary completion in 2026-12-31. Interventions recorded: Avelumab, Lorlatanib, Talazoparib, Pemetrexed, Axitinib. Conditions listed: Advanced Malignancies, NSCLC, Ovarian Cancer, Urothelial Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialSymbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With
Shares Axitinib, Pfizer (incl. Seagen).
- TrialStudy of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPC
Shares Talazoparib, Pfizer (incl. Seagen).
- TrialPF-07104091 as a Single Agent and in Combination Therapy
Shares Pfizer (incl. Seagen), Ovarian cancer.
- TreatmentBRACAnalysis CDx
Shares Talazoparib, Ovarian cancer.
- TrialStudy of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
Shares Pemetrexed, Ovarian cancer.
- CancerGestational trophoblastic neoplasia
Shares Avelumab, Pfizer (incl. Seagen).
- PathwayBase excision repair, PARP & alkylation damage
Shares Talazoparib, Ovarian cancer.
- PathwayThe angiogenic switch & tumour vessels
Shares Axitinib, Ovarian cancer.